Scotiabank Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its target price lowered by Scotiabank from $44.00 to $41.00 in a report released on Thursday morning,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock.

KROS has been the topic of a number of other research reports. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Finally, Wells Fargo & Company upped their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.22.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $10.52 on Thursday. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The stock has a market cap of $426.17 million, a PE ratio of -2.02 and a beta of 1.43. The firm has a 50-day moving average of $38.65 and a 200-day moving average of $47.61.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same period in the prior year, the company earned ($1.33) earnings per share. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. Equities research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV lifted its stake in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new position in Keros Therapeutics in the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the second quarter valued at about $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics during the third quarter valued at about $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.